BACKGROUND OF CLYRA
CLYRA Medical Technologies' innovative patent-protected copper iodine complex chemistry is based on combining compounds that create a gentle but effective oxidative reaction. This reaction is effective against a wide range of organisms that cause disease (pathogens). These organisms include viruses, fungi, spores and antibiotic-resistant strains of bacteria. CLYRA is safe, effective, bio-compatible, and cost-effective.
CLYRA Medical Technologies products are designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics. CLYRA products deliver powerful anti-microbial agents as a liquid, dry solution, hydrogel, or embedded in a pad. CLYRA products are not associated with any known acquired microbial resistance. CLYRA Medical Technologies' products can be used by wound care centers, hospitals, nursing homes, urgent care clinics and home healthcare, in military applications, and by consumers.
BACKED BY SCIENTIFIC DATA
CLYRA™ technology causes the instantaneous release of a powerful yet safe antimicrobial in measured doses when it is mixed by water from any source, including a wound exudate caused to insult an impregnated bandage. CLYRA has characterized this antimicrobial in conformance with FDA standards, and confirms that the efficacy and safety of this antimicrobial is in conformance with standards and literature on the subject. CLYRA Medical Technologies continues to push the envelope with efficacy and safety testing.
Formulations of CLYRA’s antimicrobial hydrogel and liquid wound cleanser products have passed rigorous third party laboratory testing validating both efficacy and safety. Independent testing has verified both rapid and effective control against a host of dangerous pathogens commonly encountered in the wound care field. Testing of the company’s liquid formula verified efficacy against antimicrobial resistant species referred to by the CDC as the “ESKAPE” pathogens – Enterococcus faecium (VRE), Staphylococcus aureus (MRSA), Klebsiella sp., Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.
The wound and skin care markets are established, yet continually emerging. Technology and innovation provide opportunities for improved patient care and revenue potential. However, this growth does not come without challenges. Finding a technology that is cost effective and efficacious, and that can be incorporated into a variety of products is a difficult task.
CLYRA products may solve many of the concerns that exist with current wound care and related products, and it can be positioned in all segments of healthcare. CLYRA technology has also been shown to be more effective than even the most advanced silver products, including effectiveness against Clostridium Difficle and spores. (Lab data available).
CLYRA Medical Technologies works with leaders in the wound care market, as well as in other medical and healthcare areas. CLYRA technology provides competitive advantages to companies that incorporate this technology into their product line, to more importantly make a difference in patient outcomes, as well as to provide healthcare professionals safe, cost- effective green technologies.